Ketanserin and hydralazine in hypertension in pregnancy : a randomised double-blind trial by Rossouw, H. J. et al.
specific for commercially prepared soy bean antigens
(74,4%) and the soy bean extracts that were prepared from
the soy bean dust collected on site (84,9%)." This shows
that although cross-reactivity did occur there were
differences between the commercial soy bean extracts and
the extracts prepared from dust collected on site. There may
be differences in the antigenic components of soy bean
species from different countries, and locally manufactured
RAST tests may be required. Variability in the allergen
content of soy bean SPT samples could result from the
methods used to prepare the extracts, selection of raw
material, storage conditions, standardisation, quality and
potency of extracts.'2 Human error and the interpretation of
SPTs could also account for variability of results.
The poor association between tests of sensitisation and
disease may be explained by factors associated with the
subjects themselves. High levels of soy bean dust in the
workplace are likely to produce symptoms caused by
nonspecific irritation, in which case measures of specific IgE
will clearly be inappropriate. The questionnaire as a measure
of disease outcome is problematic when not supported by
more objective methods. For example, workers may hide
symptoms to protect jobs if diagnosis of a work-related
condition may lead to dismissal. Tests for sensitisation may be
associated with particular symptom complexes and disease,
rather than with nonspecific symptoms consistent with allergic
disease. A more targeted approach may thus be indicated.
Conclusion
In this study soy bean-specific IgE tests failed to identify
workers with symptoms consistent with allergic disease.
This does not necessarily mean that these tests are not
useful, as many remedial factors may explain the
disappointing results. The tests were associated with
exposure, however, an important factor given that exposure
may be denied· or unknown.
We thank the factory management for access to the factory,
tile workers for their co-operation and Ruth Mkwelo-Radebe
and Kate Hlazana for administering the questionnaires.
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pregnancy - a randomised
double-blind trial
H. J. Rossouw, G. Howarth, H. J. Odendaal
Objectives. To compare ketanserin with hydralazine in the
treatment of hypertension in late pregnancy.
Study design. Randomised control trial. Ten milligrams
ketanserin were compared with 5 mg hydralazine, both
given intravenously to 10 patients in each group. Blood
pressure, maternal and fetal heart rate and umbilical and
arcuate artery Doppler flow velocimetry waveforms were
recorded before and every 10 minutes after administration
of the drug.
Results. No significant differences were found between
the two drugs in respect of initial blood pressures and
readings taken 10 minutes after each 30-minute
administration. One patient in the hydralazine group
developed severe hypotension and fetal distress for which
a caesarean section was performed. No change in the flow
velocity waveforms of umbilical and arcuate arteries was
noticed.
Conclusion. No unforeseen complications followed the
administration of ketanserin. No major differences in the
effects of the two drugs could be detected. Ketanserin
appears to be safer as no hypotension occurred, and it
reduced blood pressure more gradually. As ketanserin
could become an alternative to hydralazine, more studies
with larger numbers of patients are needed to compare it
with hydralazine.
S Atr Med J 1995; 85: 525-528.
Hypertension complicates 7 - 10% of pregnancies and is
associated with high maternal and fetal morbidity and
mortality.',2 The most frequent cause of maternal mortality in
pre-eclampsia is cerebral haemorrhage.' Antihypertensive
therapy can prevent this severe complication and can help
postpone delivery for 48 hours during which time steroids
can improve lung maturity in preterm infants.4
Hydralazine, a vasodilator, is at present most frequently
used in hypertensive crises during pregnancy.5 Its use
however, has disadvantages and side-effects, namely
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hypotensive episodes with fetal distress, variation in peak
effect, headaches, tachycardia, SLE-Iike syndrome and
tachyphylaxis.o-a There is therefore a need for new drugs with
fewer side-effects. The serotonin antagonist ketanserin is a
possibility.
Type 2-serotonin receptors are present on platelets and
the smooth muscle of blood vessels." Serotonin aggregates
platelets and augments the vasoconstrictor response to
angiotensin 11, histamine and catecholamines. Aggregation
of platelets releases serotonin into the serum. 'O As patients
with pre-eclampsia are more sensitive to the pressure
response to angiotensin 11 and have lowered platelet
counts"'" it can thus be postulated that serotonin plays a
role in the pathophysiology of pre-eclampsia.
Ketanserin is a 5-hydroxytryptamine type 2-receptor
antagonist with 21-adrenoreceptor activity, and selectively
blocks these receptors. '3 Studies have shown that
ketanserin effectively lowers blood pressure in puerperal and
pregnant patients and in a patient with pre-eclampsia where
intra-uterine death had occurred.",1.,15 However, there are no
studies to demonstrate its effect on uteroplacental vascular
resistance. Before large randomised controlled trials are
undertaken, in-depth studies are needed to exclude possible
harmful changes in uteroplacental vessels.
A double-blind randomised control trial was therefore
undertaken to compare the antihypertensive effects of
hydralazine and ketanserin and to study their effects on
fetal heart rate and especially on umbilical and arcuate
artery flow velocity waveforms.
Patients and methods
Patients who are more than 28 weeks pregnant and have a
diastolic blood pressure more than 110 mmHg after 5
minutes' rest, or 100 mmHg or more on two occasions at
least 30 minutes apart, were selected for the study. Patients
with the following conditions were excluded: fetal distress,
antihypertensive treatment during the preceding 12 hours
and epidural anaesthesia. Magnesium sulphate therapy was
not regarded as a contraindication for inclusion in the study.
A Doppler 9000 continuous wave machine with a 4 MHz
transducer and 200 Hz filter was used to measure the flow-
velocity waveforms of the umbilical artery. A mean of 5
consecutive waveforms was used to calculate the resistance
index (RI). Measurements were only made when the
umbilical vein waveform was also visible and while the fetus
was still and not breathing. Arcuate artery flow velocity
measurements were done in a similar way. All measurements
in a specific patient were taken on the same side. Two
measurements were taken to calculate a mean RI before the
drugs were given. After the drug administration,
measurements were repeated every 10 minutes at the same
level. Each patient received 80 ml/h of a balanced electrolyte
solution (Plasmalyte B from Sabax) intravenously. After
informed consent had been obtained, patients were
randomised by means of sealed envelopes to receive either
ketanserin or hydralazine. A person not involved in the
clinical management of the patient prepared the drugs for
injection. In the case of hydralazine the syringe was filled
with a 2 ml solution containing 5 mg of the drug. In the case
of ketanserin the syringe contained 10 mg of the drug, also
in a 2 ml solution. Therefore, it was impossible for the
clinician to know which drug was being used. The drug was
slowly administered intravenously over 2 minutes and
repeated after 20 minutes if the desired reduction of
diastolic blood pressure to below 100 mmHg had not been
obtained.
Ten patients received either ketanserin or hydralazine.
Doppler results were available in 18 patients of whom 9
received hydralazine and 9 received ketanserin. Four of the
ketanserin group and 6 of the hydralazine group received
magnesium sulphate of which 4 g were given intravenously
and 10 g intramuscularly as a loading dose and thereafter
5 g intramuscularly every 4 hours. Each of the patients
receiving hydralazine received only one dose (5 mg) to reach
the therapeutic goal, while 6 of the patients receiving
ketanserin needed 10 mg, 3 patients needed 20 mg and 1
patient needed 30 mg to reach the therapeutic goal.
As some of the patients needed more than one dose of
ketanserin to reach the therapeutic goal, results obtained
before administration of the agents and during the first.30
minutes thereafter were used to compare the two groups of
patients. The effects of ketanserin and hydralazine were
firstly assessed separately in each group, after which the
two groups were compared with each other in respect of
systolic and diastolic blood pressure and maternal pulse and
fetal heart rate.
Student's t-test was used to compare maternal age,
gravidity, birth weight and duration of pregnancy. The one-
way analysis of variance (ANOVA) was used to evaluate the
effect of the two drugs on mean systolic and diastolic blood
pressure, pulse rate and fetal heart rate. To compare the
frequency of proteinuria in the two groups, Fisher's exact
test was used. A P-value < 0,05 was significant. The study
was approved by the Tygerberg Hospital Ethics Committee.
Results
The two groups of patients were comparable in respect of
age, gravidity, duration of pregnancy and body mass (Table I).
Proteinuria was present in 9 of the 10 patients who received
ketanserin as well as in 8 of the 10 who received hydralazine.
Severe proteinuria (3+ or more on dipstick testing) was
present in 4 of the patients who received hydralazine.
No patient in the ketanserin group had severe proteinuria.
This difference was significant (Fisher's exact test, P < 0,05).
Table I. Comparison of patients. who received either ketanserin or
hydralazine (mean values and ranges)
Ketanserin Hydralazine P-value
Age (yrs) 24 26,6 0,54
(15-36) (15 - 40)
Gravidity 2 2 0,59
(1 - 6) (1 - 4)
Birth weight 2465 2329 0,55
(9) (1 040 - 3 680) (1 040 - 3 640)
Pregnancy 37,1 35,6 0,27
duration (wks) (31 -41) (30 - 39)
The mean systolic blood pressure in the ketanserin group
of patients was 147 mmHg before administration of
ketanserin, 142 mmHg after 10 minutes, 138 mmHg after 20




minutes and 130 mmHg after 30 minutes. It was not
significantly lowered in the first 30 minutes by ketanserin
(P = 0,34). Hydralazine lowered the systolic blood pressure
significantly (P < 0,001) with a-pretreatment mean reading of
155 mmHg, 140 mmHg 10 minutes after the drug had been
given, 135 mmHg after 20 minutes and 137 mmHg after
30 minutes. There was no statistical difference in the systolic
antihypertensive effect of ketanserin and hydralazine at 10,
20 and 30 minutes when compared to each other (Table 11).
There were no abnormal-velocity waveforms found with
either agent in any of the patients. (Values exceeding 95th
percentile line of curves determined for the Western Cape
population were considered abnormal.'·) Neither drug
caused any change in flow-velocity waveforms of the
umbilical or arcuate arteries (Tables VI and VII).
Table VI. RI values of the umbilical artery (mean and SO)
Ketanserin Hydralazine
Table 11. Median valUeS and ranges of systolic blood pressure
(mmHg) before and after administration of antihypertensive














Table IV. Median values and ranges of maternal pulse rate (Imin)
before and after administration of the antihypertensive drugs
Table Ill. Median values and ranges of diastolic blood pressure
(mmHg) before and after administration of the antihypertensive
drugs
Although hydralazine had a tendency to cause maternal
tachycardia, neither agent had a statistically significant
influence on maternal pulse rate or fetal heart rate (Tables IV
and V).
Ketanserin Hydralazine P-value
Before admin. 110 (110 - 120) 110 (105 - 125) 0,14
After 10 min 100 (80 - 113) 95 (85 - 110) 0,74
After 20 min 95 (80 - 110) 90 (80 - 95) 0,09














Table VII. RI values of the arcuate artery (mean and SO)
The only complication directly related to ketanserin was
dizziness, which occurred in 1 patient 10 minutes after
administration. It cleared spontaneously after 15 minutes. In
contrast, 1 patient in the hydralazine group who was 30
weeks pregnant developed severe complications of acute
hypotension, namely convulsions and severe fetal distress,
30 minutes after administration of the agent. After
resuscitation, a live infant of 1 040 g was delivered by
caesarean section. Another patient experienced tachycardia
of 120/min and a headache 30 minutes after administration
of hydralazine. Although probably not directly related to the
use of hydralazine, 2 patients developed an abruption of the
placenta 5 and 6 hours respectively after the study had been
completed. One of these fetuses died. One of the 10
patients receiving ketanserin was delivered by caesarean
section. This particular patient, 31 weeks pregnant,
developed eclampsia 2 days after completion of the study.
The fetus weighed 1 040 g and did well neonatally. There
were 5 caesarean sections in the hydralazine group. The
indications for these were an increase in the severity of
pre-eclampsia, fetal distress (due to hypotension), failed






155 (145 - 180)
140 (120 - 160)
135 (11 0 - 150)
137 (100 - 145)
147 (140 - 210)
142 (120 - 200)
138 (110 - 190)





The mean diastolic blood pressure before administration
of ketanserin was 110 mmHg, 100 mmHg after 10 minutes,
95 mmHg after 20 minutes and 90 mmHg after 30 minutes.
This lowering of diastolic blood pressure in the ketanserin
group was significant (P = 0,001). The corresponding blood
pressure in the hydralazine group was 110 mmHg before
administration, 95 mmHg after 10 minutes and 90 mmHg
after 20 minutes. This reduction in diastolic blood pressure
was also significant (P < 0,001). When compared to each
other there was no difference in the diastolic effect over 10,
20 and 30 minutes (Table Ill).
Ketanserin Hydralazine P-value
Before admin. 82 (64 - 96) 82 (72 - 100) 0,14
After 10 min 80 (72 - 104) 90 (64 - 104) 0,81
After 20 min 80 (96 - 108) 88 (76 -112) 0,15
After 30 min 84 (64 - 108) 94 (60 - 120) 0,21
Table V. Mean values and ranges of the fetal heart rate (Imin) before
and after administration of the antihypertensive drugs
Ketanserin Hydralazine P-value
Before admin. 143 (128 - 178) 138 (125 - 146) 0,73
After 10 min 144 (126 - 180) 136 (128 - 158) 0,70
After 20 min 144 (120 - 176) 139 (120 - 150) 0,75
After 30 min 146 (135 - 180) 137 (60 - 148) 0,07
Discussion
The high maternal mortality rate associated with severe pre-
eclampsia and eclampsia necessitates the use of
antihypertensive drugs in these patients.!,2 As parenteral
administration of hydralazine is often complicated by late
decelerations of the fetal heart rate, especially in the growth-
retarded fetus, there is a need for the use of safer drugs.
A sudden and substantial decline in maternal blood pressure
in the case of placental insufficiency is particularly
undesirable. Previous experience with ketanserin
demonstrated that a sudden fall in blood pressure was
unlikely.9,l5 This was again confirmed in this study where the
systolic blood pressure did not fall below 110 mmHg or the
•
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diastolic blood pressure below 85 mmHg. In contrast, the
lowest systolic and diastolic blood pressures recorded in the
hydralazine group were 100 and 60 mmHg respectively.
Although ketanserin administration did not significantly lower
the systolic blood pressure in the first 30 minutes, this could
have been a result of the small numbers as the mean
systolic blood pressure in effect declined from 147 mmHg to
130 mmHg. As the second administration was effective in
lowering the blood pressure further, it probably reflects the
safe and gradual effect of ketanserin. It should, however, be
remembered that the patients in the hydralazine group could
have had more severe pre-eclampsia, as reflected in the
higher initial blood pressure (although not significantly so)
and more severe proteinuria.
As no changes in the Doppler flow-velocity waveforms
were observed, a sudden alteration in the placental or
uterine resistance was excluded. However, as flow-velocity
waveforms do not give an indication of blood flow, one
cannot make too many conclusions from the constant f1ow-
velocity patterns. As no patient demonstrated absent end-
diastolic flow, the study did not reflect patients with high
placental resistance and thus intra-uterine growth
retardation; one cannot therefore make too many
conclusions from the small effect on the flow-velocity
waveforms. Because a several-fold increase in placental
resistance due to umbilical artery constriction is necessary
to influence the flow-velocity waveforms, minor changes will
not be noted.17 Although the greater number of caesarean
sections in the hydralazine group can certainly not be
attributed to this drug, this finding as well as the
uncontrolled fall in blood pressure raise some questions
regarding its safety. This is further supported by the findings
of Vinck et al. that the fetus was growth-retarded in 92,8%
of instances when late decelerations occurred after
antihypertensive therapy."'" On the other hand, patients in
the hydralazine group had more severe pre-eclampsia and
the greater number of caesarean sections in this group
could have occurred by chance.
This study has shown that the administration of ketanserin
during labour is free of severe adverse effects, but was too
small to demonstrate advantages over hydralazine. As
ketanserin has the potential to be an alternative drug to
hydralazine, more randomised control trials are needed to
compare them.
We wish to thank the Chief Medical Superintendent of
Tygerberg Hospital, Or G. A. Schoombie, for permission to
publish. This study was supported by the Medical R@§earch
Council.
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50 years ago . ..
The ideal condition would be for Government laboratories
to manufacture drugs and control their distribution and sale
through Government dispensaries, health centres and
pharmacies. Until such time as this can be achieved, the
following recommendations are suggested:
1. A Government department (Food, Drugs and Cosmetics)
with inspectors to be charged with the duty of enforcing
these recommendations.
2. Prohibition of secret remedies.
3. Proprietary medicines to be registered and to have
disclosed on advertisements and labels clearly and distinctly
full qualitative and quantitative details of the constituents.
4. Prohibition in medical advertisements and on labels of
preparations of names of diseases recommended for
treatment ...
5. Prohibition of false and misleading advertisements and
illustrations.
6. Price control, as during war-time. Vitamins to be made
available at low cost.
Further steps to be taken:
7. Education of young and old regarding what should not be
done and what can be done in the event of illness.
Government health centres would help in this regard.
8. Establishment of adequate medical services within easy
reach of every member of the population.
(N. Sapeika, S A Medical Journal, 23 June 1945, p 202).
